Sunitinib
- Generic Name
- Sunitinib
- Brand Names
- Sutent, Sunitinib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C22H27FN4O2
- CAS Number
- 557795-19-4
- Unique Ingredient Identifier
- V99T50803M
- Background
Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formul...
- Indication
Sunitinib is indicated for the following conditions:
- Associated Conditions
- Gastrointestinal Stromal Tumor (GIST), Renal Cell Carcinoma (RCC), Renal Cell Carcinoma Recurrent, Unresectable, locally advanced Progressive Neuroendocrine Tumors of pancreatic origin, Unresectable, metastatic Progressive Neuroendocrine Tumors of pancreatic origin
- Associated Therapies
- -
Study of Combination of Sirolimus and Sutent in Patients With Advanced Solid Tumors Non-Curable With Standard Therapy
- First Posted Date
- 2006-11-22
- Last Posted Date
- 2013-12-18
- Lead Sponsor
- Yale University
- Target Recruit Count
- 18
- Registration Number
- NCT00402415
- Locations
- 🇺🇸
Yale Comprehensive Cancer Center at Yale University School of Medicine, New Haven, Connecticut, United States
Perifosine + Sunitinib Malate for Patients With Advanced Cancers
- First Posted Date
- 2006-11-14
- Last Posted Date
- 2014-02-19
- Lead Sponsor
- AEterna Zentaris
- Target Recruit Count
- 15
- Registration Number
- NCT00399152
Sunitinib in Treating Patients With Metastatic Pancreatic Cancer That Progressed After First-Line Therapy With Gemcitabine
- First Posted Date
- 2006-11-10
- Last Posted Date
- 2013-06-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 64
- Registration Number
- NCT00397787
- Locations
- 🇺🇸
Cancer and Leukemia Group B, Chicago, Illinois, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Sunitinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- First Posted Date
- 2006-11-10
- Last Posted Date
- 2014-05-14
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 18
- Registration Number
- NCT00398112
- Locations
- 🇺🇸
North Central Cancer Treatment Group, Rochester, Minnesota, United States
Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium
- Conditions
- Interventions
- First Posted Date
- 2006-11-09
- Last Posted Date
- 2016-01-25
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 78
- Registration Number
- NCT00397488
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Study Of Sunitinib In Combination With Docetaxel Vs Docetaxel In Patients With Advanced Breast Cancer
- First Posted Date
- 2006-10-31
- Last Posted Date
- 2012-07-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 594
- Registration Number
- NCT00393939
- Locations
- 🇬🇧
Pfizer Investigational Site, Wolverhampton, United Kingdom
Sunitinib in Treating Patients With Relapsed or Refractory Diffuse or Mediastinal Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2006-10-26
- Last Posted Date
- 2014-05-15
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 19
- Registration Number
- NCT00392496
- Locations
- 🇨🇦
National Cancer Institute of Canada Clinical Trials Group, Kingston, Ontario, Canada
Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma
- Conditions
- Interventions
- First Posted Date
- 2006-10-26
- Last Posted Date
- 2014-05-21
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 39
- Registration Number
- NCT00392444
- Locations
- 🇨🇦
National Cancer Institute of Canada Clinical Trials Group, Kingston, Ontario, Canada
Sunitinib Malate in Treating Patients With Uterine Cervical Cancer That is Stage IVB, Recurrent, or Cannot Be Removed By Surgery
- First Posted Date
- 2006-10-19
- Last Posted Date
- 2015-02-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 19
- Registration Number
- NCT00389974
- Locations
- 🇨🇦
National Cancer Institute of Canada Clinical Trials Group, Kingston, Ontario, Canada
Sunitinib in Treating Young Patients With Refractory Solid Tumors
- Conditions
- Childhood Central Nervous System Embryonal TumorChildhood Central Nervous System GerminomaChildhood Central Nervous System Germ Cell TumorChildhood Central Nervous System Mixed Germ Cell TumorChildhood Central Nervous System TeratomaCentral Nervous System MetastasesChildhood Central Nervous System ChoriocarcinomaChildhood Central Nervous System Yolk Sac TumorRecurrent Childhood Central Nervous System Embryonal TumorUnspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- First Posted Date
- 2006-10-13
- Last Posted Date
- 2014-01-28
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 35
- Registration Number
- NCT00387920
- Locations
- 🇨🇦
Hospital for Sick Children, Toronto, Ontario, Canada
🇺🇸Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
🇺🇸Children's National Medical Center, Washington, District of Columbia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.